Lancet (London, England)

Retatrutide's effects in adults with obesity and type 2 diabetes in a controlled phase 3 trial

Updated

Abstract

Retatrutide, an agonist of GIP, GLP-1, and glucagon receptors, is under investigation for treating obesity and type 2 diabetes.

  • Retatrutide may help in managing obesity and type 2 diabetes.
  • The drug is also being assessed for its potential effects on knee osteoarthritis and obstructive sleep apnoea.
  • Efficacy and safety in adults with obesity and type 2 diabetes are the primary focus of the ongoing investigation.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free